Systemic adverse events and all-cause mortality following same-session bilateral intravitreal anti-VEGF injections: a systematic review
Research output: Contribution to journal › Review › Research › peer-review
Standard
Systemic adverse events and all-cause mortality following same-session bilateral intravitreal anti-VEGF injections : a systematic review. / Bjerager, Jakob; Hajari, Javad; Klefter, Oliver Niels; Subhi, Yousif; Schneider, Miklos.
In: Graefe's Archive for Clinical and Experimental Ophthalmology, 2024.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Systemic adverse events and all-cause mortality following same-session bilateral intravitreal anti-VEGF injections
T2 - a systematic review
AU - Bjerager, Jakob
AU - Hajari, Javad
AU - Klefter, Oliver Niels
AU - Subhi, Yousif
AU - Schneider, Miklos
N1 - Publisher Copyright: © 2024, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2024
Y1 - 2024
N2 - Purpose: To review the risk of systemic adverse events and all-cause mortality following same-day bilateral anti-VEGF injections. Methods: Twelve literature databases were searched for studies on same-session bilateral intravitreal anti-VEGF injections. Studies reporting on systemic adverse events and mortality were included. Data extraction was made independently by two authors and discussed afterwards until consensus was reached. Results: Seven studies were included with a total of 13,406 intravitreal anti-VEGF injections (6703 bilateral injections sessions) given to 689 patients. Across all studies, mean age of patients ranged from 55.7 to 82.5 years, and mean follow-up times ranged from 1.3 to 41 months. Six studies reported on systemic adverse events: Two cases of non-fatal cardiac adverse events were reported after 12,964 injections (6482 bilateral injection sessions) in 626 patients. Four studies reported on death: 12 deaths were recorded after 6233 bilateral injection sessions in a total population of 554 subjects. Conclusions: We suggest that the risk of non-fatal systemic adverse events and death after same-session bilateral anti-VEGF injection is reasonably low, but larger studies with follow-ups of several years are needed to quantify the exact risk. Study registration.: Prospectively registered in PROSPERO, registration ID: CRD42023428254, registration date: 20/05/2023. [Figure not available: see fulltext.].
AB - Purpose: To review the risk of systemic adverse events and all-cause mortality following same-day bilateral anti-VEGF injections. Methods: Twelve literature databases were searched for studies on same-session bilateral intravitreal anti-VEGF injections. Studies reporting on systemic adverse events and mortality were included. Data extraction was made independently by two authors and discussed afterwards until consensus was reached. Results: Seven studies were included with a total of 13,406 intravitreal anti-VEGF injections (6703 bilateral injections sessions) given to 689 patients. Across all studies, mean age of patients ranged from 55.7 to 82.5 years, and mean follow-up times ranged from 1.3 to 41 months. Six studies reported on systemic adverse events: Two cases of non-fatal cardiac adverse events were reported after 12,964 injections (6482 bilateral injection sessions) in 626 patients. Four studies reported on death: 12 deaths were recorded after 6233 bilateral injection sessions in a total population of 554 subjects. Conclusions: We suggest that the risk of non-fatal systemic adverse events and death after same-session bilateral anti-VEGF injection is reasonably low, but larger studies with follow-ups of several years are needed to quantify the exact risk. Study registration.: Prospectively registered in PROSPERO, registration ID: CRD42023428254, registration date: 20/05/2023. [Figure not available: see fulltext.].
KW - Adverse event
KW - Anti-VEGF
KW - Bilateral
KW - Death
KW - Injection
KW - Intravitreal
KW - Mortality
KW - Risk
KW - Same-day
KW - Same-session
KW - Systematic review
U2 - 10.1007/s00417-023-06368-8
DO - 10.1007/s00417-023-06368-8
M3 - Review
C2 - 38194112
AN - SCOPUS:85181882978
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
SN - 0721-832X
ER -
ID: 379706560